ERBB2 and breast carcinoma: When breast cancers were subdivided into different molecular classifications, CREB3L1 mRNA expression did not significantly influence the relapse-free survival time for luminal B (ER+ and/or PR+, HER+ or HER2– with high Ki67) (Fig. 7c) and HER2 (Fig. 7d) breast cancer patients.